Categories: CancerNews

Invitation to Presentation of Cantargia’s Interim Report January – September 2024

LUND, SE / ACCESSWIRE / November 01, 2024 / Cantargia (STO:CANTA) Cantargia (Cantargia AB; Nasdaq Stockholm:CANTA) invites investors, analysts and the press to a presentation of the interim report for January – September 2024 at 3 pm (CET) on November 15, 2024. The report will be published at 07:00 am (CET) the same day.

In conjunction to the report, Cantargia invites investors, analysts, and media to an audiocast with teleconference (in English) on November 15, at 3:00 pm (CET), where Cantargia’s CEO, Göran Forsberg, and CFO, Patrik Renblad, will present Cantargia and comment on the report, followed by a Q&A-session.

If you wish to participate via webcast, please use the link below. Via the webcast you will be able to ask written questions. Webcast: https://ir.financialhearings.com/cantargia-q3-report-2024 .

If you wish to participate via teleconference, please register on the link below. After registration you will be provided phone numbers and a conference ID to access the conference. You can ask questions verbally via the teleconference: https://conference.financialhearings.com/teleconference/?id=50048870 .

The webcast will also be available on demand on Cantargia’s corporate website: www.cantargia.com

For further information, please contact
Göran Forsberg, CEO
Telephone: +46 (0)46-275 62 60
E-mail: goran.forsberg@cantargia.com

About Cantargia
Cantargia AB (publ), reg. no. 556791-6019, is a biotechnology company that develops antibody-based treatments for life-threatening diseases and has established a platform based on the protein IL1RAP, involved in a number of cancer forms and inflammatory diseases. Cantargia’s oncology program, the antibody nadunolimab (CAN04), is being studied clinically, primarily in combination with chemotherapy with a focus on pancreatic cancer, non-small cell lung cancer and triple-negative breast cancer. Positive data for the combinations indicate stronger efficacy than would be expected from chemotherapy alone. Cantargia’s second development program, the antibody CAN10, blocks signaling via IL1RAP in a different manner than nadunolimab and addresses treatment of serious autoimmune/inflammatory diseases, with initial focus on hidradenitis suppurativa and systemic sclerosis.

Cantargia is listed on Nasdaq Stockholm (ticker: CANTA). More information about Cantargia is available at www.cantargia.com .

Attachments
Invitation to presentation of Cantargia’s interim report January – September 2024

SOURCE: Cantargia

View the original press release on accesswire.com

Staff

Recent Posts

Pioneering Scientist David Deamer to receive ABRF Award for Outstanding Contributions to Biomolecular Technologies

 LEXINGTON, Ky. , Nov. 2, 2024 /PRNewswire/ -- The Association of Biomolecular Resource Facilities (ABRF) is…

1 day ago

Optimal Breathing Holds its Annual Black Friday Sale

Turbo Oxygen EWOt System with 900 Liter Oxygen Reservoir Bag and Patented Mega-Flow Mask with…

1 day ago

Nihon Kohden Introduces First-Ever ATO-Certified Ventilators

IRVINE, Calif.--(BUSINESS WIRE)--#RespiratoryCare--Nihon Kohden, a global leader in medical technology, today announced the introduction of…

2 days ago

2025 Medicare Physician Fee Schedule Final Rule Includes Two Major Wins for Therapy Providers

APTA advocacy leads to impactful policy wins that will reduce administrative burden, improve access, and…

2 days ago

Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

NEWTON, Mass., Nov. 1, 2024 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical…

2 days ago

Gestalt and Paige Partner to Enhance Digital Pathology Workflows with Integration of Advanced AI Algorithms

SPOKANE, Wash. and NEW YORK, Nov. 1, 2024 /PRNewswire/ -- Gestalt, a leader in digital pathology…

2 days ago